Key Highlights

  • Oklo (NYSE:OKLO) said on November 11, 2026 that the US Department of Energy cleared the final operations hold point for its Groves Isotope Test Reactor, known as Groves-1, in Lockhart, Texas.
  • The clearance allows unrestricted operations for research, testing and training, and the shares rose on the news during a broad market rally.
  • Groves-1 reached first criticality at low power in August 2026, less than a year after groundbreaking, under the DOE Reactor Pilot Program.
  • Experience from the reactor will feed into Groves-2 Forge, a planned isotope production pilot initially focused on lutetium-177 for cancer therapy.

What the Clearance Means

For Oklo (NYSE:OKLO), the DOE decision moves Groves-1 from a start-up phase into a working research and demonstration reactor. The company plans to use it to train personnel, test equipment such as control rod drive mechanisms and benchmark criticality and reactivity data. That operating record matters because the company has no commercial power reactors running yet, and investors have valued it largely on future plans. Each regulatory step that turns a design into a functioning Facility reduces execution risk. The milestones have arrived quickly in 2026: approval of the safety analysis on July 1, startup authorisation on July 23 and first criticality announced on August 6, followed now by clearance for unrestricted operations. The DOE Reactor Pilot Program was set up to speed up advanced reactor testing, and Groves-1 is among the projects showing that the pathway can work within months rather than years. For a young company, demonstrating that it can design, build and operate a reactor safely is a credibility test with regulators, customers and investors alike.

The Isotope Business

Groves-1 also underpins a second Business line. Oklo plans to use what it learns at the site for Groves-2 Forge, a pilot for producing and processing medical and industrial isotopes, starting with lutetium-177. That isotope is used in targeted radiopharmaceuticals for prostate and neuroendocrine cancers, a market growing quickly as large drugmakers expand their radioligand therapies. Supply of medical isotopes has often been tight because it depends on a small number of ageing research reactors around the world. An isotope business could produce Revenue earlier than the company's planned Aurora power plants, which still need licensing and construction before they deliver electricity. That makes the Texas site an important bridge between today's development spending and future commercial income. It also gives Oklo a customer base in healthcare that is less tied to the timing of data centre construction.

Risks and What to Watch

Oklo remains a pre-revenue company with a valuation built on expectations for advanced nuclear power to supply data centres and industry. Licensing of its commercial reactors by the Nuclear Regulatory Commission, fuel supply for high-assay low-enriched uranium and construction costs remain the main hurdles. The shares have been highly volatile, swinging with sentiment on AI power Demand and nuclear policy. Investors in Oklo (NYSE:OKLO) will watch early operating data from Groves-1, progress on Groves-2 Forge, licensing steps for its first Aurora plant and any customer agreements that convert interest into binding contracts. Cash spending will rise as projects advance, so funding needs and any new share sales are another factor. Broader policy support for nuclear power in Washington remains a tailwind, but political priorities can shift.

Where Things Stand

The DOE has cleared Oklo's Groves-1 test reactor in Texas for unrestricted research, testing and training, following first criticality in August 2026. The reactor gives the company operating experience and a base for a lutetium-177 isotope business. Commercial power plants remain years away, so licensing progress and customer contracts will continue to drive the Investment case. The clearance is a step forward in a long development path.